Chorioamnionitis — Comprehensive Disease Research Report

Prepared: 2026-08-04 · Target: dismech knowledge base entry (kb/disorders/Chorioamnionitis.yaml) · Category: Infectious

Read this first — snippet discipline. Every quoted passage below is tagged [VERBATIM] (pulled from the PubMed abstract page and believed to be an exact substring) or [PARAPHRASE] (the fetch returned a summarizer's rewording — do not paste it into an evidence.snippet: field). Per the dismech SOP, run just fetch-reference PMID:XXXXXXX and just validate-references on every citation before committing. Every ontology ID in this report is a candidate and must survive just validate-terms; I've flagged confidence explicitly in §16.

1. Disease Information

What it is

Chorioamnionitis is inflammation of the fetal membranes — the amnion and chorion — and, by extension, of the amniotic fluid, umbilical cord, decidua and sometimes the fetus itself. Think of the amniotic sac as a sealed fermentation vessel: it's supposed to be a closed, low-microbe compartment, and chorioamnionitis is what happens when something breaches the seal (or when the vessel's own tissue starts screaming without any invader at all). The condition sits at the intersection of infection, sterile inflammation, and the physiological inflammatory program of labor itself, which is exactly why its nomenclature has been fought over for a decade.

Three overlapping entities travel under the name, and conflating them is the single biggest curation trap here:

ACOG's definition: "Intraamniotic infection, also known as chorioamnionitis, is an infection with resultant inflammation of any combination of the amniotic fluid, placenta, fetus, fetal membranes, or decidua." [VERBATIM] — ACOG Committee Opinion No. 712, Obstet Gynecol 2017;130(2):e95-e101 (PMID:28742677).

The "Triple I" reclassification (2015–2016)

In January 2015 an NICHD expert panel convened specifically because the word "chorioamnionitis" had become a semantic swamp:

"The panel noted that the term chorioamnionitis has been used to label a heterogeneous array of conditions characterized by infection and inflammation or both with a consequent great variation in clinical practice for mothers and their newborns. Therefore, the panel proposed to replace the term chorioamnionitis with a more general, descriptive term: 'intrauterine inflammation or infection or both,' abbreviated as 'Triple I.'... It is particularly important to recognize that an isolated maternal fever is not synonymous with chorioamnionitis." [VERBATIM] — Higgins RD, Saade G, Polin RA, et al. Obstet Gynecol 2016;127(3):426-436 (PMID:26855098).

Triple I diagnostic tiers (NICHD 2016): - Isolated maternal fever — oral temp ≥39.0 °C once, or 38.0–38.9 °C persisting on repeat at 30 min. No other findings. - Suspected Triple I — fever plus ≥1 of: baseline fetal tachycardia (>160 bpm for ≥10 min); maternal WBC >15,000/mm³ without corticosteroids; definite purulent cervical discharge. - Confirmed Triple I — suspected Triple I plus objective laboratory confirmation: positive amniotic fluid Gram stain, low AF glucose, positive AF culture, or placental pathology showing diagnostic infection/inflammation.

ACOG (CO 712, 2017) then softened this back toward practical bedside use: suspected IAI is diagnosed when "the maternal temperature is greater than or equal to 39.0°C or when the maternal temperature is 38.0–38.9°C and one additional clinical risk factor is present." [VERBATIM] (PMID:28742677). Note that ACOG deliberately kept the term "intraamniotic infection" rather than adopting "Triple I" — the two vocabularies coexist in current literature. Adoption of Triple I has been patchy, and dismech should probably curate the entity under the historical name with both definitional frameworks captured as definitions[] blocks.

Identifiers

Synonyms / alternative names

Amnionitis · intraamniotic infection (IAI) · intra-amniotic infection · intrauterine infection · amniotic infection syndrome · "Triple I" (intrauterine inflammation or infection or both) · acute chorioamnionitis (histologic) · membranitis · placental acute inflammation · ascending intrauterine infection. Related-but-distinct terms that should not be merged: funisitis (umbilical cord inflammation — a fetal response), chorionic vasculitis, deciduitis, villitis of unknown etiology (chronic, non-infectious, different lesion class), chronic chorioamnionitis (a distinct lymphocytic lesion of late preterm birth).

Data provenance

Both individual-patient and aggregate. Clinical chorioamnionitis is a routine EHR/administrative diagnosis (ICD-10 O41.12-, present in birth certificate data and in large claims/registry sets like NIS, Kaiser, Consortium on Safe Labor), which makes it a good candidate for a computable phenotype definitions[] block. The mechanistic literature, by contrast, is dominated by a small number of amniocentesis-based cohorts (chiefly the NICHD Perinatology Research Branch, Wayne State/Detroit and Seoul National University), which are individual-patient but highly selected. Placental pathology data come from institutional pathology series standardized (since 2016) by the Amsterdam consensus.

2. Etiology

2.1 Primary causal factors

Chorioamnionitis is not a genetic disease. It is an acquired, largely infectious/inflammatory condition with four recognized causal routes and one large sterile category.

Route 1 — Ascending infection from the lower genital tract (dominant, ~majority of preterm cases). Organisms move cervix → choriodecidual space → chorion/amnion → amniotic fluid → fetus. Romero's canonical staging:

• Stage I — alteration of vaginal/cervical flora, or pathogenic organisms in the cervix (bacterial vaginosis is the archetype).
• Stage II — organisms cross into the choriodecidual space and reside in the lower uterine pole between membranes and chorion (deciduitis / choriodeciduitis).
• Stage III — organisms breach the amnion into the amniotic cavity (amnionitis / intra-amniotic infection); may involve chorionic plate vessels (choriovasculitis).
• Stage IV — fetal involvement: aspiration/swallowing of infected fluid → congenital pneumonia, otitis, conjunctivitis; hematogenous spread → fetal bacteremia and sepsis.

Histologic progression follows the same order — chorio-deciduitis is the early stage, chorio-deciduo-amnionitis the advanced stage of ascending intrauterine infection (PMID:26574743).

Route 2 — Hematogenous / transplacental. Rare but important. Listeria monocytogenes is the archetype; recent molecular work supports hematogenous dissemination on the basis of "acute intervillositis and the detection of L. monocytogenes in the amniotic fluid and intervillous space of the placenta combined with the absence of this organism in the vagina" [PARAPHRASE — reverify] (PMID:40643048). Also Treponema pallidum, Mycobacterium tuberculosis, Brucella, Coxiella burnetii, and some viruses.

Route 3 — Iatrogenic / retrograde. Amniocentesis, chorionic villus sampling, fetoscopy, cerclage placement, intrauterine transfusion, retained IUD, amnioinfusion, internal fetal/uterine monitoring. Retrograde spread from the fallopian tubes into the peritoneal cavity is a fourth theoretical route (rarely documented).

Route 4 — Sterile intra-amniotic inflammation (no organism at all). This is the plot twist of the last fifteen years and it must be represented in the pathograph. In preterm labor with intact membranes:

"(i) The frequency of sterile intra-amniotic inflammation was significantly greater than that of microbial-associated intra-amniotic inflammation [26% (35/135) versus 11% (15/135); (P = 0.005)], (ii) patients with sterile intra-amniotic inflammation delivered at comparable gestational ages had similar rates of acute placental inflammation and adverse neonatal outcomes as patients with microbial-associated intra-amniotic inflammation, and (iii) patients with sterile intra-amniotic inflammation and high AF concentrations of HMGB1 (≥8.55 ng/mL) delivered earlier than those with low AF concentrations of HMGB1 (P = 0.02)." [VERBATIM] — Romero R, Miranda J, Chaiworapongsa T, et al. Am J Reprod Immunol 2014;72(5):458-74 (PMID:25078709).

Route 5 (term-specific) — epidural-associated systemic maternal inflammation. At term, "clinical chorioamnionitis" is frequently neither infection nor even intra-amniotic: "Clinical chorioamnionitis is a syndrome caused by intraamniotic infection, sterile intraamniotic inflammation (inflammation without bacteria), or systemic maternal inflammation induced by epidural analgesia." [PARAPHRASE — reverify] — Jung E, Romero R, et al. Am J Obstet Gynecol 2024;230(3S):S807-S840 (PMID:38233317). Epidural-related fever is associated with elevated serum IL-6 and IL-8 and is essentially never microbial (PMID:21343762); one term series found grade 1–2 histologic chorioamnionitis in 34% of placentas with actual infection in only 4%.

2.2 Microbiology (see also §5.3)

Amniotic fluid isolates in preterm labor, in rough order of frequency: genital mycoplasmas — Ureaplasma urealyticum / Ureaplasma parvum (the single most common), Mycoplasma hominis; anaerobes — Fusobacterium nucleatum, Sneathia (Leptotrichia) sanguinegens, Bacteroides spp., Peptostreptococcus; facultative organisms — Gardnerella vaginalis, Streptococcus agalactiae (GBS), Escherichia coli, Enterococcus, Streptococcus anginosus group; fungi — Candida albicans (strongly associated with cerclage and retained IUD). Infection is usually polymicrobial.

Molecular methods substantially outperform culture: 16S rRNA sequencing detects uncultivable organisms including Sneathia, Leptotrichia, Bergeyella, Clostridiales, and oral-origin taxa (PMID:19144804, J Clin Microbiol 2008). Fusobacterium nucleatum is a periodontal organism, supporting the oral-hematogenous seeding hypothesis for a subset of cases.

2.3 Risk factors

Obstetric / mechanical (strongest, and mostly modifiable-ish):

Microbiological/colonization: GBS colonization, bacterial vaginosis, Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, cervical insufficiency with exposed membranes, short cervix, prior preterm birth, periodontal disease.

Host/demographic: young maternal age; nulliparity; obesity (high BMI); smoking; alcohol; immunocompromise (HIV — histologic acute chorioamnionitis prevalence studied in Ugandan HIV+ cohorts, PMC6459589); anemia; low socioeconomic status; African-American ancestry (confounded by access and by BV prevalence); prior clinical chorioamnionitis (population-based recurrence risk documented in Washington State 1989–2008, PMC3587161).

Gestational age is the single most powerful "risk factor" for the histologic lesion. Histologic acute chorioamnionitis prevalence is "3-5% at term, increasing to 94% at 21-24 weeks" [PARAPHRASE — reverify] — Kim CJ, Romero R, et al. Am J Obstet Gynecol 2015;213(4 Suppl):S29-52 (PMID:26428501). This inverse relationship is the most important epidemiological fact about the disease.

2.4 Protective factors

• Intrapartum antibiotic prophylaxis for GBS — reduces early-onset GBS disease >80% (1.8 → 0.23 per 1,000 live births) but is a neonatal-outcome intervention more than a chorioamnionitis-prevention one.
• Latency antibiotics in PPROM (ampicillin+erythromycin, "Mercer protocol") — prolong latency and reduce chorioamnionitis incidence (Mercer et al., JAMA 1997; ORACLE I, Lancet 2001).
• Limiting digital cervical examinations after ROM; sterile speculum preference.
• Vaginal cleansing with povidone-iodine or chlorhexidine before cesarean — reduces postoperative endometritis (Cochrane).
• Azithromycin-based extended-spectrum prophylaxis at unscheduled cesarean (C/SOAP trial, Tita et al., N Engl J Med 2016) — reduces post-cesarean infection.
• Treatment of bacterial vaginosis — protective in high-risk women in some but not all trials; screening/treating unselected low-risk women has not reproducibly reduced preterm birth. Curate this as equivocal.
• Genetic protective alleles: none established. Some cytokine-promoter "low-producer" genotypes (e.g., IL-6 −174 GG, TNF −308 GG) have been reported as lower-risk in individual studies, but these are inconsistent and should be curated as PARTIAL or omitted.

2.5 Gene–environment interaction

The best-characterized GxE signal in this space is TNF genotype × bacterial vaginosis:

Maternal carriers of the TNF-2 allele (TNF −308A) had increased risk of spontaneous preterm birth (OR 2.7, 95% CI 1.7–4.5); "The association between TNF-2 and preterm birth was modified by bacterial vaginosis, with those having a susceptible genotype and bacterial vaginosis showing increased odds of preterm birth compared with those who did not (OR 6.1, 95% CI 1.9-21.0)" [PARAPHRASE — reverify] — Macones GA, et al. Am J Obstet Gynecol 2004 (PMID:15284722).

This is a genuinely useful dismech pattern: environmental exposure (BV) × host inflammatory genotype → amplified inflammatory response → preterm birth. Caveat it heavily — a subsequent meta-analysis found no statistically significant association between TNF −308G>A and preterm birth overall, and later work (PMID:15507966) implicated TNF −863 rather than −308. Curate as an EMERGING/contested hypothesis with an explicit KNOWLEDGE_GAP discussion, not as settled mechanism.

3. Phenotypes

3.1 Maternal clinical phenotypes (intrapartum)

Note that the classic "malodorous fluid + uterine tenderness" triad is a late and insensitive finding; most cases present as fever plus tachycardia in a laboring nullipara with an epidural.

3.2 Fetal / neonatal phenotypes

3.3 Characteristics

• Onset: exclusively gestational/perinatal. Maternal phenotype is intrapartum or, in preterm cases, antepartum. Neonatal phenotypes are congenital-to-neonatal onset, with a long-term neurodevelopmental tail into childhood.
• Severity: variable and gestational-age-dependent. "Chorioamnionitis was severe in 74% of preterm but in only 15% of term deliveries."
• Progression: acute and episodic-to-progressive. Untreated intra-amniotic infection progresses over hours-to-days; the histologic lesion progresses through defined stages. Once delivery occurs the maternal disease is self-limited; the fetal sequelae are not — FIRS-associated brain and lung injury is progressive over months to years.
• Duration: maternal — self-limited (resolves within days of delivery and antibiotics). Neonatal — potentially lifelong (cerebral palsy, chronic lung disease).
• Quality of life: maternal QoL impact is short-term but real (fever, pain, higher cesarean rate, postpartum hemorrhage, longer stay, breastfeeding disruption, NICU separation). Offspring QoL impact is where the burden actually lives — CP and severe neurodevelopmental disability carry lifelong disability weights (GBD). No chorioamnionitis-specific EQ-5D/SF-36 literature exists; use CP- and prematurity-specific instruments (e.g., PedsQL Cerebral Palsy Module, GMFCS-stratified utilities) as proxies and label the linkage as inferential.

4. Genetic / Molecular Information

Bottom line: there are no causal genes. Chorioamnionitis is not Mendelian, has no OMIM entry, no pathogenic variants, no ClinVar submissions as a monogenic condition, no chromosomal abnormalities, and no genetic testing indication. Anything a deep-research tool tells you about "causal genes for chorioamnionitis" is a hallucination or a Named Entity Confusion event — apply the just preflight-dr logic mentally: MONDO:0000409 records no RO:0004003 causal gene, so a DR preflight would return SKIP, and the manual checks apply.

What does exist is a modest, largely non-replicated susceptibility-variant literature. Curate these with relationship_type: SUSCEPTIBILITY and inheritance_term: HP:0010982 (polygenic) only if you can quote a real abstract; otherwise leave the genetic: block empty.

A useful HuGE review of preterm-birth genetics exists (Genetic variation associated with preterm birth: A HuGE review, Genet Med) — treat it as the umbrella citation for "many candidate genes, little replication."

Epigenetics. Emerging and thin. Reported: differential placental DNA methylation in histologic chorioamnionitis; cord-blood methylation signatures of intrauterine inflammation; histone-modification-mediated priming of the fetal innate immune compartment (trained immunity) after in-utero LPS/Ureaplasma exposure in animal models. No validated epigenetic biomarker exists. Curate as KNOWLEDGE_GAP.

Chromosomal abnormalities: none. Somatic variation: not applicable. Modifier genes: not established.

5. Environmental Information

5.1 Environmental / exposure factors

• Iatrogenic instrumentation — the dominant "environmental" exposure: digital cervical exams, internal monitors, amniocentesis, cerclage, IUD retention, amnioinfusion.
• Air pollution / particulate matter — associated with preterm birth generally; a direct chorioamnionitis link is not established.
• Occupational exposures — no established specific link.
• Heat exposure / ambient temperature — confounds fever-based diagnosis; no causal link.

5.2 Lifestyle factors

Cigarette smoking (↑ risk, and ↑ PPROM); alcohol use (↑ risk, listed among StatPearls risk factors); illicit drug use; obesity/high BMI; poor periodontal health (periodontitis → oral organisms in amniotic fluid, notably F. nucleatum); nutritional deficiency; sexual activity and vaginal douching (via microbiome disruption); short interpregnancy interval.

5.3 Infectious agents (with NCBI Taxonomy IDs)

On Ureaplasma specifically — the "commensal" framing is wrong:

"Patients with preterm premature rupture of membranes and microbial invasion of the amniotic cavity with U urealyticum are associated with a robust host inflammatory response in the fetal, amniotic, and maternal compartments." [VERBATIM] — Yoon BH, Romero R, et al. Am J Obstet Gynecol 1998;179(5):1254-60 (PMID:9822511). In that series, histologic chorioamnionitis was present in 100% (22/22) of U. urealyticum-positive cases vs 42% (30/72) of culture-negative cases.

6. Mechanism / Pathophysiology

Here's the causal chain, told as one continuous story, then decomposed into pathograph nodes.

6.1 Narrative causal chain

A shift in the vaginal microbiome (loss of Lactobacillus dominance, rise of BV-associated anaerobes) removes the chemical fence at the cervix. Organisms — or, in the sterile route, host debris and stress signals from stretched, aging membranes — reach the choriodecidual interface. There, pattern-recognition receptors on decidual stromal cells, chorionic trophoblast, amnion epithelium, and resident macrophages read the signal: TLR4 for Gram-negative LPS, TLR2/TLR6 for lipoproteins and mycoplasmal lipoproteins, TLR9 for bacterial CpG DNA, and RAGE/TLR4 for the alarmin HMGB1 in the sterile arm. Both microbial PAMPs and sterile DAMPs converge on the same receptor plumbing — which is exactly why sterile and microbial intra-amniotic inflammation produce indistinguishable placental pathology and comparably bad neonatal outcomes.

Receptor engagement activates MyD88 → IRAK → TRAF6 → IKK → NF-κB and, in parallel, the MAPK cascades. NF-κB drives transcription of IL-1β, IL-6, IL-8/CXCL8, TNF-α, CCL2, and the NLRP3 inflammasome components. Assembled NLRP3 inflammasome → caspase-1 → mature IL-1β and IL-18, plus gasdermin-D-mediated pyroptosis of amnion and decidual cells — this is the amplification step that turns a signal into a syndrome.

Three downstream output arms then run in parallel:

1. Chemotaxis arm. CXCL8/IL-8 and CXCL1/2 establish a gradient into the amniotic cavity. Maternal neutrophils exit decidual venules and march through chorion into amnion (the maternal inflammatory response, MIR). Later, fetal neutrophils cross chorionic-plate vessel walls and umbilical vessels into Wharton's jelly (the fetal inflammatory response, FIR = chorionic vasculitis + funisitis). This directional two-source neutrophil traffic is histologic chorioamnionitis.
2. Uterotonic arm. IL-1β and TNF-α upregulate PTGS2/COX-2 and phospholipase A2, releasing arachidonic acid and generating prostaglandins E2 and F2α, while downregulating HPGD (15-hydroxyprostaglandin dehydrogenase), the enzyme that normally destroys them. Prostaglandins plus increased GJA1/connexin-43 and oxytocin-receptor expression convert the quiescent myometrium into a contractile syncytium → preterm labor.
3. Tissue-destruction arm. Neutrophil and amnion-derived MMP-8 (neutrophil collagenase) and MMP-9 (gelatinase B), plus elastase, degrade the amniochorionic collagen scaffold; TIMPs fall; the membranes lose tensile strength → PPROM. The same proteases plus IL-8-driven neutrophil influx into the cervical stroma cause collagen remodeling → cervical ripening.

Meanwhile, the fetus mounts its own systemic response. Fetal plasma IL-6 rises, defining FIRS:

"A systemic fetal inflammatory response, as determined by an elevated fetal plasma interleukin-6 value, is an independent risk factor for the occurrence of severe neonatal morbidity." [VERBATIM — conclusion sentence] — Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM. Am J Obstet Gynecol 1998;179(1):194-202 (PMID:9704787).

FIRS is multi-organ. In the lung, aspirated infected fluid plus cytokines cause fetal pneumonitis and paradoxical "inflammatory lung maturation" (surfactant up, alveolarization and microvascular development down) → the arrested-development phenotype of BPD. In the brain, circulating IL-1β/IL-6/TNF-α plus systemic hypotension activate microglia; pre-oligodendrocytes — exquisitely vulnerable at 23–32 weeks — die by oxidative and excitotoxic injury; myelination fails → periventricular leukomalacia and later cerebral palsy. In the gut, inflammatory priming plus impaired mesenteric perfusion predisposes to NEC. In the eye, altered IGF-1/VEGF signaling contributes to ROP. In the heart/vasculature, cytokines impair ductal closure → PDA. The thymus involutes.

There are two immunologically distinct flavors of FIRS:

FIRS Type I shows "upregulation of host immune responses, including neutrophil and monocyte functions, together with a proinflammatory cytokine storm"; FIRS Type II shows "a mild chronic inflammatory response involving perturbation of HLA transcripts, suggestive of fetal semiallograft rejection." [PARAPHRASE — reverify] — Para R, Romero R, Miller D, et al. ImmunoHorizons 2021;5(9):735-751 (PMID:34521696). Type I is defined by cord IL-6 >11 pg/mL + acute funisitis; Type II by cord CXCL10 >82.34 pg/mL + chronic placental inflammation + cord IL-6 <11 pg/mL. Only Type I belongs on this entry; Type II belongs with chronic chorioamnionitis / villitis of unknown etiology.

6.2 Suggested pathograph nodes

Note the elegant/annoying duality worth flagging as a mechanistic_hypotheses pair: the same inflammatory mediator load that drives preterm labor also impairs term myometrial contractility (→ cesarean and postpartum hemorrhage). Curate as two hypothesis groups (preterm_uterotonic_activation vs term_myometrial_suppression) rather than as a single contradictory edge — the mechanisms differ by gestational age and receptor context (PMID:29848185).

6.3 Molecular profiling

• Transcriptomics / single-cell. The reference resource is the human placenta single-cell atlas of parturition: "Cell types most affected by labor were fetal stromal and maternal decidual cells in the chorioamniotic membranes (CAMs) and maternal and fetal myeloid cells in the placenta. Cell-cell interaction analyses showed that CAM and placental cell types participated in labor-driven maternal and fetal signaling, including the collagen, C-X-C motif ligand (CXCL), tumor necrosis factor (TNF), galectin, and interleukin-6 (IL-6) pathways." [VERBATIM] — Garcia-Flores V, Romero R, Tarca AL, et al. Sci Transl Med 2024;16(729):eadh8335 (PMID:38198568). Companion resources: single-cell atlas of murine reproductive tissues during preterm labor (Cell Rep 2022); single-cell transcriptional signatures of the human placenta in term and preterm parturition (eLife 2019, Pique-Regi et al.).
• Proteomics. Amniotic fluid proteomic "MR score" (Buhimschi/Weiner) — a 4-biomarker SELDI-TOF fingerprint (defensin-2, defensin-1, S100A12, S100A8) predicting intra-amniotic inflammation and neonatal sepsis (PLOS Med 2007, 4(1):e18).
• Metabolomics. Amniotic fluid glucose depletion is the oldest metabolic signature (mean 5 ± 2.4 mg/dL in IAI vs 39.8 ± 18.4 mg/dL without). Elevated AF lactate and altered LDH isoform mapping also reported. NMR/MS metabolomic signatures of intra-amniotic infection exist but are not clinically deployed.
• Lipidomics. Prostaglandin and platelet-activating-factor species elevated in amniotic fluid; lysophosphatidylcholine and oxidized-lipid signatures reported. Thin literature.
• Functional genomics. No CRISPR/RNAi screens specific to chorioamnionitis. TLR4-antagonist pharmacological "screens" in NHP/rodent stand in for this (PMC2774271).

7. Anatomical Structures Affected

Primary (maternal-fetal interface): - Chorion — UBERON:0003124 (verify) - Amnion — UBERON:0000305 (verify) - Chorioamniotic (extraembryonic/fetal) membranes — verify best UBERON parent, possibly UBERON:0000478 extraembryonic structure - Decidua — UBERON:0002450 (verify) - Placenta — UBERON:0001987 (verify) - Amniotic fluid — UBERON:0000173 (verify) - Umbilical cord (incl. Wharton's jelly) — UBERON:0002331 (verify) - Uterus / myometrium — UBERON:0000995 / UBERON:0001296 (verify) - Uterine cervix — UBERON:0000002 (verify) - Vagina — UBERON:0000996 (verify)

Secondary (fetal/neonatal end-organ): lung (UBERON:0002048), brain — specifically periventricular white matter and germinal matrix (UBERON:0002316 white matter, verify), intestine (UBERON:0000160), eye/retina (UBERON:0000970 / UBERON:0000966), heart/ductus arteriosus (UBERON:0001496 verify), thymus (UBERON:0002370).

Body systems: reproductive, immune, respiratory, nervous, digestive, cardiovascular.

Tissue types: amniotic squamous/cuboidal epithelium; chorionic trophoblast; decidual and chorionic connective/stromal tissue; myometrial smooth muscle; umbilical vascular endothelium and smooth muscle; Wharton's jelly (specialized mucous connective tissue).

Cell populations (Cell Ontology candidates): - neutrophil — CL:0000775 (the defining cell of the lesion) - macrophage — CL:0000235; Hofbauer cell (fetal placental macrophage) — verify - decidual stromal cell — verify CL term - trophoblast cell — CL:0000351 - amnion epithelial cell — verify - fibroblast / stromal cell — CL:0000057 / CL:0000499 - T cell — CL:0000084; regulatory T cell — CL:0000815 (depleted/skewed by Ureaplasma) - natural killer cell — CL:0000623 (decidual NK) - endothelial cell of umbilical vein — verify (HUVEC-adjacent) - microglial cell — CL:0000129 (verify) — fetal brain injury arm - oligodendrocyte precursor / pre-oligodendrocyte — verify — the vulnerable target in PVL - uterine smooth muscle cell — CL:0002601 (verify)

Subcellular (GO Cellular Component): NLRP3 inflammasome complex (GO:0072559, verify); plasma membrane TLR complexes; endosome (TLR9 signaling); nucleus (NF-κB translocation); extracellular region/matrix (GO:0031012); neutrophil azurophil/specific granules (verify); mitochondrion (ROS, mtDNA release as a DAMP).

Localization / lateralization: the ascending lesion is characteristically most severe at the lower uterine pole / membrane rupture site and around the cervical os, tapering toward the placental disc — this gradient is itself diagnostic of the ascending route. Not lateralized in the left/right sense. Funisitis affects the umbilical vein first (phlebitis), then arteries (arteritis), which is a stageable temporal marker.

8. Temporal Development

Onset. Congenital/gestational by definition. Antepartum in the PPROM/preterm-labor route; intrapartum in the term route. Onset pattern is acute to subacute (hours to days), though a low-grade Ureaplasma colonization can smolder for weeks — the "very chronic ureaplasma colonization" of the fetal sheep model.

Stages. Use the two complementary staging systems:

Romero clinical/microbiological staging (ascending route) — Stage I cervicovaginal dysbiosis → Stage II choriodeciduitis → Stage III intra-amniotic infection (amnionitis, choriovasculitis) → Stage IV fetal infection.

Amsterdam consensus histologic staging (Khong TY, Mooney EE, Ariel I, et al., Arch Pathol Lab Med 2016;140(7):698-713, PMID:27223167) — two axes:

• Maternal inflammatory response (MIR): Stage 1 acute subchorionitis/chorionitis; Stage 2 acute chorioamnionitis (neutrophils in the amnion/chorionic connective tissue); Stage 3 necrotizing chorioamnionitis (amniocyte necrosis, karyorrhexis, basement-membrane thickening). Grade 1 = not severe; Grade 2 = severe (confluent inflammation or subchorionic microabscesses).
• Fetal inflammatory response (FIR): Stage 1 chorionic vasculitis or umbilical phlebitis; Stage 2 umbilical arteritis (involvement of ≥1 umbilical artery); Stage 3 necrotizing funisitis. Grade 1/2 by severity, Grade 2 requiring near-confluent intramural neutrophils with attenuation of vascular smooth muscle.

Amsterdam recognizes "only stages 2–3 to represent a fully developed histological chorioamnionitis, with stage 1 being a sensitive but less specific indicator" — an important curation nuance, since much of the older literature counts Stage 1 as positive and therefore reports inflated prevalences.

Progression rate. Rapid once intra-amniotic invasion occurs. Untreated, the interval from intra-amniotic infection to delivery is typically short (days); severity of neonatal outcome tracks both organism and duration of exposure. Progression from chorio-deciduitis to chorio-deciduo-amnionitis is measurable in days (PMID:26574743).

Course. Maternal: acute, self-limited, resolving with delivery + antibiotics. Fetal/neonatal: acute illness followed by either recovery or a progressive/static-disability course (BPD improving over years; CP static but with evolving functional consequences).

Remission. Maternal remission is treatment-induced and near-universal with delivery + antibiotics. Notably, intra-amniotic infection can be eradicated with antibiotics without delivering in a subset — see §12.

Critical periods. - 23–32 weeks — the pre-oligodendrocyte vulnerability window for white-matter injury; also the canalicular/saccular lung window where inflammation arrests alveolarization. - Latency period after PPROM — the intervention window for latency antibiotics + antenatal corticosteroids + magnesium sulfate. - ≥18 hours ROM — the inflection point for infection risk and for GBS prophylaxis indication. - Intrapartum, first 4 hours of fever — the window in which myometrial contractility declines (~2 hours post-fever onset), driving the cesarean/atony risk.

9. Inheritance and Population

Epidemiology

Incidence expressed per 100,000 for the dismech Prevalence block: clinical chorioamnionitis ≈ 1,290–5,000 per 100,000 live births (measure_type: BIRTH_PREVALENCE, prevalence_class: ABOVE_1_IN_1000, rate_per_100000: 1290 for the national-administrative estimate; add a second record for the histologic lesion at term, ~3,000–5,000/100,000, and a third for the 21–24-week stratum at ~94,000/100,000 which is the striking one). Use population: for the cohort and put the verbatim source phrasing in notes:.

Inheritance

Not applicable as a Mendelian trait. If an inheritance: block is curated at all, it should be HP:0010982 Polygenic inheritance with relationship_type: SUSCEPTIBILITY on the contributing genes, and the block description must state plainly that the condition is acquired and infectious/inflammatory with only modest, unreplicated host-genetic modification. There is no penetrance, expressivity, anticipation, germline mosaicism, founder effect, consanguinity role, or carrier frequency to curate. Do not invent these.

Population demographics

• Geographic: global; higher burden in low- and middle-income settings tracking untreated genital infection, limited antenatal care, and higher preterm-birth rates (sub-Saharan Africa, South Asia). US data show substantial regional and institutional variation driven partly by diagnostic-threshold differences.
• Ancestry/ethnicity: higher reported rates in Black and Hispanic US populations. This tracks BV prevalence, preterm-birth disparity, and healthcare access — curate as an epidemiological association with an explicit note that no genetic basis is established. Getting this framing wrong is a real harm; be careful.
• Sex ratio: the maternal condition is by definition female. For the fetal/neonatal phenotypes, male fetuses have somewhat worse inflammation-associated outcomes (male disadvantage in preterm neurodevelopmental injury), a consistent but modest effect.
• Age distribution: maternal — reproductive age, with elevated risk at the young extreme (<20 years). Neonatal — perinatal onset with sequelae presenting through early childhood.

10. Diagnostics

Clinical criteria

As in §1: NICHD Triple I tiers (isolated fever / suspected / confirmed) and ACOG CO 712 thresholds. The clinical diagnosis is sensitive but poorly specific — the central diagnostic problem of this disease.

Laboratory tests

Maternal blood: CBC with differential (WBC >15,000/mm³, left shift; confounded by corticosteroids and by labor itself), CRP, procalcitonin (better specificity than CRP for true infection), blood cultures (positive in a minority), lactate if sepsis suspected.

Amniotic fluid (via amniocentesis — the reference standard, but invasive and rarely performed at term):

An important curation point: AF IL-6/MMP-8 define inflammation; culture/PCR define infection. The 2×2 of these two axes (microbial-associated inflammation / sterile inflammation / colonization without inflammation / neither) is the correct mechanistic taxonomy and should shape the definitions[] and biochemical blocks.

Fetal/neonatal: cord-blood IL-6 (>11 pg/mL defines FIRS type I), cord CXCL10 (>82.34 pg/mL, FIRS type II), neonatal CBC with I:T ratio, CRP, procalcitonin, blood culture, CSF if indicated, gastric aspirate/surface cultures (low yield, largely abandoned).

LOINC anchors (verify all): serum glucose, WBC count, CRP, procalcitonin, IL-6, and the amniotic-fluid analyte codes. Given your loinc-no-reference-ranges memory, do not attempt to source reference intervals from LOINC — cite the primary literature intervals above and put non-citable lab-manual provenance in notes:.

Imaging and functional tests

• Ultrasound: limited direct value. Findings suggesting infection: absent fetal breathing movements, biophysical profile ≤6, oligohydramnios after PPROM, "sludge" (dense amniotic-fluid debris near the internal os — a marker of intra-amniotic infection and short cervix), short cervical length, thickened/echogenic membranes. In Listeria chorioamnionitis, characteristic fetal ultrasound features are described (PMID:23429225).
• Electronic fetal monitoring: baseline fetal tachycardia >160 bpm; reduced FHR variability; absent accelerations. FHR patterns in chorioamnionitis carry independent CP risk information (PMID:36433630).
• Neonatal cranial ultrasound / MRI: IVH, cystic PVL, diffuse white-matter injury.
• No role for maternal CT/MRI/PET.

Histopathology (the reference standard for the lesion)

Placental examination per Amsterdam criteria: staged and graded MIR and FIR as in §8. Immunohistochemistry (CD15, myeloperoxidase) can help distinguish maternal vs. fetal neutrophils in ambiguous cases; XY-FISH or HLA-typing definitively assigns neutrophil origin in research settings. Necrotizing funisitis implies chronic (days-to-weeks) fetal inflammation and carries the worst neurodevelopmental prognosis.

Genetic testing

None indicated. Not applicable: WGS, WES, gene panels, single-gene testing, CMA, karyotype, FISH, mtDNA testing, repeat-expansion testing. This is worth stating explicitly in the entry so downstream tools don't infer absence-of-evidence.

Omics-based diagnostics

• Proteomics: AF proteomic MR score (defensins + S100 proteins) — validated in research settings, not clinically deployed.
• Transcriptomics: maternal-blood placenta-derived scRNA-seq signatures detectable in circulation and predictive of spontaneous preterm birth (Garcia-Flores 2024, PMID:38198568) — the most promising non-invasive avenue.
• Metabolomics: AF NMR/MS signatures — research only.
• Liquid biopsy: cell-free RNA/DNA in maternal plasma — emerging.
• Cervicovaginal fluid proteomics — patented approaches exist; not standard of care.

Differential diagnosis

Screening

• Universal antenatal GBS screening at 36 0/7 – 37 6/7 weeks (ACOG 2020 / AAP; stewardship moved from CDC to ACOG+AAP in 2018) — not screening for chorioamnionitis per se, but the main population-level intervention in this space.
• BV screening: recommended only in symptomatic women or high-risk (prior preterm birth) contexts; USPSTF recommends against screening asymptomatic low-risk pregnant persons.
• Cervical length screening in women with prior spontaneous preterm birth — identifies the high-risk group.
• No newborn/carrier/cascade screening applies.

11. Outcome / Prognosis

Maternal

• Mortality: very low in high-resource settings (<0.1%); maternal sepsis from chorioamnionitis remains a meaningful contributor to maternal death in low-resource settings.
• Morbidity: "Maternal morbidity from intraamniotic infection also can be significant, and may include dysfunctional labor requiring increased intervention, postpartum uterine atony with hemorrhage, endometritis, peritonitis, sepsis, adult respiratory distress syndrome and, rarely, death." [VERBATIM] — ACOG CO 712 (PMID:28742677). Add: cesarean delivery (2–3× increased), wound infection, pelvic abscess, septic pelvic thrombophlebitis, necrotizing fasciitis (rare), blood transfusion, prolonged hospitalization.
• Recovery: essentially complete with treatment. Recurrence risk in a subsequent pregnancy is elevated (population-based, PMC3587161).
• Important negative: "Intraamniotic infection alone is rarely, if ever, an indication for cesarean delivery." [VERBATIM] — ACOG CO 712.

Neonatal — short term

Pooled effect sizes worth curating (each needs its own PMID + verified snippet): - Early-onset sepsis: combined OR 3.45 (95% CI 2.02–5.89) for chorioamnionitis overall in preterm infants; histologic chorioamnionitis unadjusted pooled OR 4.42 (2.68–7.29) for confirmed EOS and 5.88 (3.68–9.41) for any EOS (Frontiers in Immunology 2020 systematic review/meta-analysis/meta-regression, PMC7289970). - Composite adverse neonatal outcomes: approximately 2- to 3.5-fold increased odds of perinatal death, EOS, septic shock, pneumonia, meningitis, IVH, cerebral white-matter damage, ROP, NEC, and long-term disability including CP. - PDA: significant association on meta-analysis (PMC4574167). - Funisitis specifically carries worse short-term prematurity outcomes than chorioamnionitis alone (frequentist + Bayesian meta-analysis, PMID:36830092).

Neonatal — long term

"Using a random effects model, clinical chorioamnionitis was significantly associated with both cerebral palsy (RR, 1.9; 95% CI, 1.4-2.5) and cPVL (RR, 3.0; 95% CI, 2.2-4.0) in preterm infants. The RR of histologic chorioamnionitis and cerebral palsy was 1.6 (95% CI, 0.9-2.7) in preterm infants, and histologic chorioamnionitis was significantly associated with cPVL (RR, 2.1; 95% CI, 1.5-2.9). Among full-term infants, a positive association was found between clinical chorioamnionitis and cerebral palsy (RR, 4.7; 95% CI, 1.3-16.2)." [VERBATIM] — Wu YW, Colford JM Jr. JAMA 2000;284(11):1417-1424 (PMID:10989405).

Additional long-term: bronchopulmonary dysplasia and childhood respiratory morbidity/asthma; neurodevelopmental impairment and lower cognitive scores; increased long-term infectious morbidity of offspring (PMID:38337508); associations with autism spectrum disorder and schizophrenia in the broader maternal-immune-activation literature (weaker, confounded — curate as EMERGING with a KNOWLEDGE_GAP).

Prognostic factors

Gestational age at exposure (dominant); presence and stage of funisitis (fetal, not just maternal, response — much stronger predictor); cord IL-6 >11 pg/mL (FIRS); necrotizing funisitis (worst); organism identity (Candida, GBS, E. coli worse than Ureaplasma alone for acute sepsis; Ureaplasma disproportionately associated with BPD); duration of ROM; maternal antibiotic administration; antenatal corticosteroid exposure; birthweight; male sex; presence of chronic vs acute inflammation.

Prognostic biomarkers: cord-blood IL-6, CXCL10; AF MMP-8 and IL-6; neonatal CRP/procalcitonin trajectory; the AF proteomic MR score.

12. Treatment

Maternal — intrapartum antibiotics (standard of care)

Per ACOG CO 712 (PMID:28742677): "Administration of intrapartum antibiotics is recommended whenever an intraamniotic infection is suspected or confirmed."

Adjuncts: antipyretics (acetaminophen — CHEBI:46195, verify) — reduces maternal and fetal tachycardia and may reduce unnecessary intervention; delivery is the definitive therapy for the maternal disease (but not an automatic indication for cesarean); IV hydration; oxytocin augmentation with anticipation of atony; active management of the third stage.

Modality tags: therapeutic_modality: SMALL_MOLECULE for the antibiotics, SURGERY for cesarean, SUPPORTIVE→ use NCIT:C15747 Supportive Care with BEHAVIORAL/OTHER as appropriate.

Preterm-specific / expectant-management regimens

• PPROM latency antibiotics — "Mercer protocol": IV ampicillin 2 g + erythromycin 250 mg q6h × 48 h, then oral amoxicillin 250 mg + erythromycin base 333 mg q8h × 5 days. Prolongs latency, reduces chorioamnionitis, reduces prematurity-related neonatal morbidity (Mercer BM et al., JAMA 1997).
• ORACLE I (Lancet 2001): erythromycin improved short-term neonatal outcomes in PPROM; co-amoxiclav prolonged pregnancy but significantly increased neonatal necrotizing enterocolitis — hence the standing prohibition on amoxicillin-clavulanate in PPROM. This is a great WRONG_STATEMENT/harm-of-treatment evidence item.
• Azithromycin substitution for erythromycin — comparable latency, possibly lower chorioamnionitis and postpartum endometritis rates (PMC7368187); increasingly the practical default given erythromycin supply issues.
• Intra-amniotic infection eradication (Yoon/Romero regimen): ceftriaxone + clarithromycin + metronidazole. "The rates of intra-amniotic inflammation and intra-amniotic inflammation/infection in patients who received regimen 2 decreased during treatment from 68.8% to 52.1% and from 75% to 54.2%, respectively... intra-amniotic inflammation/infection was eradicated in 33.3% of patients who received regimen 2, but in none who received regimen 1." [VERBATIM] — Lee J, Romero R, Kim SM, Chaemsaithong P, Yoon BH. J Matern Fetal Neonatal Med 2016;29(17):2727-37 (PMID:26441216). In preterm labor with intact membranes, eradication was confirmed in 79% of those with follow-up amniocentesis (PMID:30928566). This is a genuinely under-appreciated therapeutic finding and deserves an EMERGING hypothesis node — the field's default is "infection means deliver," and these data say a subset can be treated.
• Antenatal corticosteroids (betamethasone/dexamethasone) — administered even in the setting of chorioamnionitis at eligible gestational ages; net benefit favors administration. NCIT:C15986 + betamethasone.
• Magnesium sulfate for fetal neuroprotection <32 weeks — relevant given the PVL/CP pathway.
• Tocolysis is contraindicated in confirmed intra-amniotic infection.

Cesarean-associated prophylaxis

• Pre-incision cefazolin (standard).
• Adjunctive azithromycin 500 mg IV at unscheduled cesarean in labor or after ROM — C/SOAP trial (Tita ATN et al., N Engl J Med 2016) reduced composite postoperative infection.
• Vaginal preparation with povidone-iodine/chlorhexidine before cesarean.

Neonatal management

• Preterm exposed newborns: blood culture + empiric ampicillin + gentamicin, with de-escalation at 36–48 h if cultures negative and infant well (Puopolo KM, Benitz WE, Zaoutis TE; AAP COFN/COID, Pediatrics 2018 — separate statements for ≥35 0/7 wk and ≤34 6/7 wk).
• Well-appearing term/late-preterm exposed newborns: the field has moved decisively from "treat everyone exposed" to risk-stratified care. The Kaiser Permanente neonatal early-onset sepsis risk calculator stratifies to observe-only / observe-and-evaluate / evaluate-and-consider-treatment / evaluate-and-treat, and substantially reduces empiric antibiotic exposure without missed sepsis in the published series (PMID:29275925, PMID:29467522, PMID:37827729). "Previous CDC and AAP management strategies from 2010 to 2012 contributed to unnecessary EOS evaluations of asymptomatic newborns ≥35 weeks' gestation, including evaluation and antibiotics on all newborns exposed to chorioamnionitis regardless of clinical appearance." [PARAPHRASE — reverify]
• Supportive: respiratory support/surfactant, caffeine, thermoregulation, nutrition; NEC and BPD prevention bundles.

Not applicable

Gene therapy, cell therapy, RNA-based therapies, targeted small-molecule oncology-style therapies, immunotherapies (checkpoint inhibitors), rehabilitation for the acute maternal illness. Rehabilitation IS relevant downstream for CP-affected offspring (physical therapy NCIT:C15302, occupational therapy NCIT:C121351, speech therapy NCIT:C159273) — curate those on the sequelae, not on chorioamnionitis itself.

Experimental / trial landscape

Search ClinicalTrials.gov for: NCT registrations on azithromycin vs erythromycin for PPROM (e.g., NCT07183462 for late PPROM), intra-amniotic infection eradication regimens, antenatal N-acetylcysteine for inflammation-associated fetal brain injury, IL-1 receptor antagonist (anakinra) and the small-molecule IL-1R antagonist rytvela (101.10) for intrauterine inflammation (preclinical→early clinical), TLR4 antagonists, and probiotic/vaginal-microbiome-modulation trials. Populate clinical_trials: with just fetch-reference NCT… — do not hand-write these, and remember phase is an enum (PHASE_III, not "Phase III").

Pharmacogenomics

No established PGx for this indication. Relevant general PGx: aminoglycoside ototoxicity and MT-RNR1 m.1555A>G (CPIC guideline — a genuine, curatable, actionable gene-drug pair given that gentamicin is first-line therapy here). That's the one PGx item worth including, and it's a nice one because it's real, actionable, and specific to the standard regimen.

13. Prevention

Primary prevention - Universal antenatal GBS screening at 36 0/7–37 6/7 weeks with intrapartum penicillin prophylaxis for colonized women, ROM ≥18 h, prior GBS-affected infant, GBS bacteriuria, or intrapartum fever with unknown status. Reduced early-onset GBS disease from 1.8 → 0.23 per 1,000 live births. - Minimize digital cervical examinations, especially after ROM; prefer sterile speculum; avoid unnecessary internal monitoring. - Avoid/limit unnecessary labor induction and prolonged latent-phase management where clinically reasonable. - Treat symptomatic bacterial vaginosis, trichomoniasis, gonorrhea, chlamydia; treat asymptomatic bacteriuria. - Periodontal care in pregnancy (mechanistically motivated by F. nucleatum; randomized trials of periodontal treatment have not reduced preterm birth — curate the mechanism as plausible and the intervention as ineffective, which is a nice honest pairing). - Smoking cessation, weight management, adequate interpregnancy interval. - Aseptic technique for amniocentesis/CVS/cerclage; timely removal of retained IUD. - Vaginal cleansing before cesarean; adjunctive azithromycin at unscheduled cesarean.

Secondary prevention - Early recognition of PPROM; latency antibiotics; serial monitoring for infection (temperature, WBC, FHR, fetal movement). - Amniocentesis for AF IL-6/MMP-8/culture in selected PPROM and preterm-labor cases → antibiotic eradication attempt. - Cervical-length screening + vaginal progesterone / cerclage in the appropriate high-risk groups (prevents preterm birth, and by extension exposure). - Serial GBS-status verification; prompt intrapartum prophylaxis.

Tertiary prevention - Antenatal corticosteroids; magnesium sulfate for neuroprotection <32 weeks. - Delivery timing decisions balancing infection against prematurity. - Risk-stratified neonatal EOS evaluation (avoiding iatrogenic harm from over-treatment — antibiotic exposure in the first week is itself associated with NEC, late-onset sepsis, and microbiome disruption). - Neurodevelopmental follow-up programs for exposed preterm infants.

Immunization. No licensed vaccine prevents chorioamnionitis. Maternal GBS conjugate/protein vaccines are in advanced clinical development (Pfizer hexavalent GBS6, MinervaX) and are the most plausible future primary-prevention tool; WHO has published preferred product characteristics. Influenza and Tdap vaccination in pregnancy are unrelated to this pathway. Curate GBS vaccines as EXPERIMENTAL with therapeutic_modality: VACCINE, NCIT:C15346 vaccination.

Genetic counseling / genetic screening / PGD / prenatal genetic testing: not applicable. State this explicitly.

Public health interventions: antenatal care access and coverage; STI screening and partner treatment programs; skilled birth attendance and clean-delivery practices (WHO); antimicrobial stewardship in obstetrics and neonatology; hand hygiene and infection-control bundles on labor and delivery.

14. Other Species / Natural Disease

Chorioamnionitis and its cousin, placentitis, are genuinely important in veterinary medicine — this isn't a courtesy section.

Comparative pathology. The neutrophilic ascending-infection pattern is broadly conserved across placental mammals, but placental architecture is not — humans and NHPs are hemochorial and discoid; ruminants are epitheliochorial/cotyledonary; horses are diffuse epitheliochorial. This is the single most important caveat for cross-species extrapolation and belongs in a HUMAN_MODEL_MISMATCH discussion: an epitheliochorial placenta has more physical layers between maternal blood and fetus, which changes both microbial access and cytokine transfer. Sheep, the workhorse fetal-physiology model, are exactly the mismatch case.

Evolutionary conservation. TLR4/MyD88/NF-κB signaling, IL-1/IL-6/TNF, the NLRP3 inflammasome, MMP-8/MMP-9, and prostaglandin synthesis are deeply conserved across mammals (Alliance of Genome Resources / HomoloGene orthologs exist for all of these). The timing control of parturition, by contrast, is poorly conserved — mice depend on luteolysis/progesterone withdrawal, humans do not — which limits mouse preterm-labor models specifically.

Zoonotic potential / cross-species transmission. Real and clinically important: Coxiella burnetii (Q fever) and Chlamydia abortus from parturient small ruminants cause human placentitis, chorioamnionitis and pregnancy loss; Brucella spp.; Listeria monocytogenes (foodborne, from animal reservoirs); Toxoplasma gondii (felid definitive host). Pregnant people are specifically counseled to avoid lambing/kidding operations — a real public-health rule grounded in this mechanism.

Orthologous genes for the mechanism nodes: mouse Tlr4 (NCBI Gene 21898), Il6 (16193), Il1b (16176), Tnf (21926), Nlrp3 (216799), Ptgs2 (19225), Mmp9 (17395) — verify all IDs before curating.

15. Model Organisms

Chorioamnionitis has an unusually good and unusually large-animal-weighted model landscape, because the key readouts (fetal lung, fetal brain, chronic instrumentation) need a big fetus.

Non-human primate — rhesus macaque (Macaca mulatta, NCBITaxon:9544)

The gold standard: hemochorial discoid placenta, similar gestational immunology, chronic catheterization possible. - Intra-amniotic U. parvum: "U. parvum decreased regulatory T cells (Tregs) and activated interferon γ production in these Tregs in the fetus", with organism thriving in AF and colonizing fetal lung but only modest inflammation and no severe chorioamnionitis, plus increased uterine connexin-43 (PMID:27601620*, J Infect Dis 2016;214(10):1597-1604). [PARAPHRASE for the framing sentences — the quoted clause appears verbatim; reverify.] - Ureaplasma parvum or Mycoplasma hominis as sole pathogens cause chorioamnionitis, preterm delivery, and fetal pneumonia in rhesus macaques (Novy MJ, Grigsby PL et al., Reprod Sci 2009) — the definitive Koch's-postulate-style demonstration for genital mycoplasmas. - Intra-amniotic LPS causes acute neuroinflammation in preterm rhesus macaques (PMC5011884) — the cleanest primate link from intra-amniotic inflammation to fetal brain injury. - Intra-amniotic IL-1β → decidual neutrophil recruitment and activation (PMC4342792) — isolates the cytokine arm from the microbe. - TLR4 antagonist pretreatment inhibited LPS-induced preterm uterine contractility, cytokines and prostaglandins in rhesus monkeys (PMC2774271*) — a genuine mechanistic intervention study and the best evidence for TLR4 as a druggable node.

Sheep (Ovis aries, NCBITaxon:9940) — the fetal-lung workhorse

• Intra-amniotic E. coli LPS (typically 10 mg, 2 or 7 days before preterm delivery at ~124 d gestation) → influx of inflammatory cells into fetal lung, lung inflammation, and functional lung maturation — the classic dissociation of surfactant induction from structural maturation (Kallapur SG, Jobe AH and colleagues; PMC2660220).
• Intra-amniotic Ureaplasma parvum → chronic low-grade lung inflammation with functional maturation (PMC3006269).
• A20 (TNFAIP3) upregulation in fetal lung in the sheep LPS model (PMC8794675) — the negative-feedback/tolerance arm.
• Also used for fetal brain injury (white-matter), gut, and thymic involution readouts, and for "inflammation tolerance" (a second LPS dose produces a blunted response).
• Limitation to record: epitheliochorial cotyledonary placenta, not hemochorial; and outbred, non-genetically-tractable.

Mouse (Mus musculus, NCBITaxon:10090) — the mechanism/genetics workhorse

• Intrauterine LPS infusion model (time-pregnant CD-1; mini-laparotomy, LPS into the uterus between the first two gestational sacs) — reproducible preterm birth plus fetal brain injury (PMID:31419431, Am J Pathol 2019 characterization).
• IL-1 receptor antagonist: "IL-1 receptor blockade prevents fetal cortical brain injury but not preterm birth in a mouse model of inflammation-induced preterm birth and perinatal brain injury" (PMC3989434) — a clean dissociation of the brain-injury and parturition arms, and an important nuance for any therapeutic node.
• Intra-amniotic HMGB1 → preterm labor/birth in 57% of mice vs 0% of controls (PMID:26781934) — the sterile-inflammation proof of principle.
• Fusobacterium nucleatum induces premature and term stillbirths in pregnant mice, implicating oral bacteria (Infect Immun 2004;72(4):2272-2279).
• Nr4a1 mediates perinatal neuroinflammation in murine preterm labor (Cell Death Dis 2019).
• Single-cell atlas of murine reproductive tissues during preterm labor (Cell Rep 2022) — the mouse counterpart of the human atlas.
• Knockouts/transgenics available (MGI/IMPC/KOMP): Tlr4, Tlr2, Myd88, Il1r1, Il6, Tnf, Nlrp3, Casp1, Ptgs2, Mmp9, Trif/Ticam1. Conditional and reporter lines exist for most.
• Limitations to record: progesterone-withdrawal-dependent parturition (unlike humans); hemochorial but labyrinthine placenta; multiparous with very short gestation; systemic vs intra-amniotic route matters enormously and much of the literature uses intraperitoneal LPS, which is not the same disease.

Rabbit, rat, guinea pig

Rabbit intracervical E. coli inoculation is a classic ascending-infection model (Fidel/Gibbs). Rat and guinea-pig LPS models are used for fetal brain injury; guinea pigs have the advantage of a more human-like brain-growth trajectory.

In vitro / cellular

• Human chorioamniotic membrane explants — the direct model; e.g., "Incubation of chorioamniotic membranes with HMGB1 induced the release of mature IL-1beta and IL-6" (Biol Reprod 2016;95(6):130).
• Primary human amnion epithelial cells, chorion trophoblasts, decidual stromal cells, myometrial smooth-muscle cells (hTERT-immortalized lines).
• Cell lines: HTR-8/SVneo (extravillous trophoblast), BeWo/JEG-3 (choriocarcinoma, trophoblast surrogates), THP-1 (monocyte/macrophage), WISH (amnion-derived, but HeLa-contaminated — flag this, it's a real reproducibility landmine).
• Organ-on-chip: feto-maternal interface-on-chip (FMi-OOC), placenta-on-a-chip, and amnion membrane-on-chip systems (Menon and colleagues) — used to study ascending propagation of inflammation across membrane layers.
• Organoids/iPSCs: trophoblast organoids, endometrial/decidual organoids, iPSC-derived microglia for the neuroinflammation arm.

Phenotype recapitulation summary

Model databases: MGI, IMPC, KOMP/EuMMCR, IMSR, MMRRC, RGD, ZFIN (no meaningful zebrafish model here — no placenta), Alliance of Genome Resources, Cellosaurus, ATCC.

16. Ontology Term Candidates — verification required

Do not paste any of these into YAML without running just validate-terms. Confidence is my honest read, not a substitute for OAK.

MONDO (high confidence): MONDO:0000409 chorioamnionitis.

HPO — high confidence: HP:0001788 Premature rupture of membranes · HP:0001945 Fever · HP:0001649 Tachycardia · HP:0001974 Leukocytosis · HP:0001622 Premature birth · HP:0002098 Respiratory distress · HP:0100806 Sepsis · HP:0001643 Patent ductus arteriosus. HPO — medium, verify: HP:0011227 Elevated circulating C-reactive protein concentration · HP:0100021 Cerebral palsy · HP:0001561/HP:0001562 Polyhydramnios/Oligohydramnios. HPO — needs lookup: fetal tachycardia; periventricular leukomalacia; intraventricular hemorrhage (neonatal); necrotizing enterocolitis; bronchopulmonary dysplasia; retinopathy of prematurity; stillbirth; purulent vaginal discharge. There may be no HPO term for "chorioamnionitis" itself; the entry's identity should hang off MONDO, not HPO.

GO biological process — high confidence: GO:0006954 inflammatory response · GO:0006955 immune response · GO:0030593 neutrophil chemotaxis · GO:0032496 response to lipopolysaccharide · GO:0002224 toll-like receptor signaling pathway · GO:0001516 prostaglandin biosynthetic process · GO:0030198 extracellular matrix organization · GO:0022617 extracellular matrix disassembly · GO:0032611 interleukin-1 beta production · GO:0032635 interleukin-6 production · GO:0032640 tumor necrosis factor production · GO:0050829 defense response to Gram-negative bacterium · GO:0050830 defense response to Gram-positive bacterium · GO:0007567 parturition · GO:0006979 response to oxidative stress. GO — verify label drift: GO:0007249 (canonical NF-κB signal transduction — label was renamed; your snippet-validator-normalizes-whitespace and MONDO-obsoletion memories apply here too, check live OLS not just the local sqlite). GO molecular function: GO:0004222 metalloendopeptidase activity. GO cellular component: GO:0072559 NLRP3 inflammasome complex · GO:0031012 extracellular matrix.

CL — high confidence: CL:0000775 neutrophil · CL:0000235 macrophage · CL:0000351 trophoblast cell · CL:0000084 T cell · CL:0000815 regulatory T cell · CL:0000623 natural killer cell · CL:0000057 fibroblast. CL — needs lookup: decidual stromal cell; amnion epithelial cell; Hofbauer cell; microglial cell; oligodendrocyte precursor cell; uterine smooth muscle cell; endothelial cell of umbilical vein.

UBERON — needs verification across the board: placenta, amnion, chorion, decidua, amniotic fluid, umbilical cord, uterus, myometrium, uterine cervix, vagina, lung, brain white matter, intestine, retina.

CHEBI: CHEBI:16412 lipopolysaccharide (high) · CHEBI:15551 prostaglandin E2 (high) · CHEBI:17234 glucose (high) · CHEBI:46195 paracetamol (high) · ampicillin, gentamicin, clindamycin, azithromycin, erythromycin, metronidazole, ceftriaxone, betamethasone (all verify; per your therapeutic-agent-chebi-only-cache memory, prefer CHEBI over NCIT for therapeutic_agent).

NCIT (treatment actions): NCIT:C15986 Pharmacotherapy · NCIT:C15747 Supportive Care · NCIT:C15329 Surgical Procedure (cesarean — look for a specific cesarean-section term) · NCIT:C15346 Vaccination (GBS vaccine, experimental) · NCIT:C15302 Physical Therapy (downstream CP care).

NCBITaxon: as listed in §5.3 and §14.

17. Curation notes for the dismech entry

A few things that will save time (and reviewer round-trips) when this becomes kb/disorders/Chorioamnionitis.yaml:

• Model the sterile arm as a first-class mechanistic_hypotheses group, not a footnote. Sterile intra-amniotic inflammation is more common than microbial in preterm labor with intact membranes (26% vs 11%) and produces equivalent outcomes. An entry that treats this as purely infectious would be wrong on its own headline claim, and a reviewer will catch it. Suggested groups: microbial_associated_inflammation (CANONICAL), sterile_alarmin_driven_inflammation (CANONICAL — genuinely co-equal, not "alternative"), epidural_systemic_maternal_inflammation (ALTERNATIVE, term-specific).
• Category check. The template says Infectious. That's defensible but incomplete — consider classifications that also capture the inflammatory/perinatal dimension, and say so in the entry notes rather than silently forcing it into one bucket.
• Module conformance candidates. No existing dismech module is a clean fit. The closest structural analogy is intestinal_barrier_dysfunction's insult-agnostic convergence logic — several distinct upstream insults (microbial, sterile/alarmin, epidural-systemic) converging on one downstream inflammatory cascade. This entry is arguably a good seed for a new ascending_mucosal_barrier_infection or sterile_vs_microbial_inflammatory_convergence module later; don't force a conformance declaration now.
• Two KNOWLEDGE_GAP discussions worth writing: (1) no validated non-invasive test distinguishes microbial-associated from sterile intra-amniotic inflammation, so antibiotic decisions are made blind; (2) the causal direction between histologic chorioamnionitis and preterm labor is not fully resolved at term, where inflammation may be a consequence of labor rather than its cause.
• One HUMAN_MODEL_MISMATCH discussion: placental architecture differs fundamentally between the sheep/ruminant models (epitheliochorial) and humans (hemochorial), and mouse parturition is progesterone-withdrawal-dependent while human parturition is not — so neither the dominant fetal-physiology model nor the dominant genetics model reproduces the human timing mechanism.
• Evidence-source discipline: the sheep, macaque, and mouse citations are MODEL_ORGANISM; the chorioamniotic-membrane explant and cell-line work is IN_VITRO; the amniocentesis cohorts, meta-analyses, and guidelines are HUMAN_CLINICAL. Do not let a macaque or sheep citation be the sole support for a human phenotype node — that's a recurring reviewer finding.
• NEC (Named Entity Confusion) risk: low but non-zero. "Chorioamnionitis" is unambiguous, but watch for drift into chronic chorioamnionitis, villitis of unknown etiology, and FIRS type II — those are a different lesion class with different biology (maternal anti-fetal rejection), and a DR report that wanders into them will look coherent and validate cleanly while describing the wrong entity.
• Remember the folded-scalar hyphen rule and the square-bracket-in-snippet rule from your CI memories — several of the quotes above contain bracketed statistics (e.g., [26% (35/135) versus 11% (15/135)), which will pass a local check and then fail CI. Trim those quotes at a bracket-free boundary before committing.

Sources

Primary literature (PubMed): - Kim CJ, Romero R, et al. Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance. AJOG 2015;213(4 Suppl):S29-52 — PMID:26428501 - Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM. The fetal inflammatory response syndrome. AJOG 1998;179(1):194-202 — PMID:9704787 - Romero R, Miranda J, et al. Prevalence and clinical significance of sterile intra-amniotic inflammation. Am J Reprod Immunol 2014;72(5):458-74 — PMID:25078709 - Higgins RD, Saade G, Polin RA, et al. Evaluation and Management of Women and Newborns With a Maternal Diagnosis of Chorioamnionitis: Summary of a Workshop. Obstet Gynecol 2016;127(3):426-436 — PMID:26855098 - ACOG Committee Opinion No. 712: Intrapartum Management of Intraamniotic Infection. Obstet Gynecol 2017;130(2):e95-e101 — PMID:28742677 - Wu YW, Colford JM Jr. Chorioamnionitis as a risk factor for cerebral palsy: a meta-analysis. JAMA 2000;284(11):1417-1424 — PMID:10989405 - Khong TY, Mooney EE, Ariel I, et al. Sampling and Definitions of Placental Lesions: Amsterdam Placental Workshop Group Consensus Statement. Arch Pathol Lab Med 2016;140(7):698-713 — PMID:27223167 - Jung E, Romero R, Suksai M, et al. Clinical chorioamnionitis at term. AJOG 2024;230(3S):S807-S840 — PMID:38233317 - Yoon BH, Romero R, et al. Microbial invasion of the amniotic cavity with Ureaplasma urealyticum. AJOG 1998;179(5):1254-60 — PMID:9822511 - Lee J, Romero R, Kim SM, Chaemsaithong P, Yoon BH. A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in preterm PROM. J Matern Fetal Neonatal Med 2016;29(17):2727-37 — PMID:26441216 - Antibiotic administration can eradicate intra-amniotic infection or inflammation in preterm labor with intact membranes — PMID:30928566 - Garcia-Flores V, Romero R, et al. Deciphering maternal-fetal cross-talk in the human placenta during parturition using scRNA-seq. Sci Transl Med 2024;16(729):eadh8335 — PMID:38198568 - Para R, Romero R, et al. The Distinct Immune Nature of the Fetal Inflammatory Response Syndrome Type I and Type II. ImmunoHorizons 2021;5(9):735-751 — PMID:34521696 - Senthamaraikannan P, Presicce P, et al. Intra-amniotic Ureaplasma parvum-Induced Maternal and Fetal Inflammation in Rhesus Macaques. J Infect Dis 2016;214(10):1597-1604 — PMID:27601620 - Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med 2000;342(20):1500-7 — PMID:10816189 (no abstract) - Macones GA, et al. A polymorphism in the promoter region of TNF and bacterial vaginosis — PMID:15284722 - Adverse outcomes after preterm labor and TNF-alpha polymorphism -863 — PMID:15507966 - Timing of Histologic Progression from Chorio-Deciduitis to Chorio-Deciduo-Amnionitis — PMID:26574743 - Intra-Amniotic Administration of HMGB1 Induces Spontaneous Preterm Labor and Birth — PMID:26781934 - DAMPs in preterm labor and preterm PROM: HMGB1 — PMID:21958433 - Association of epidural-related fever and noninfectious inflammation in term labor — PMID:21343762 - Molecular evidence for hematogenous dissemination of Listeria monocytogenes intraamniotic infection — PMID:40643048 - Utility of Early-Onset Sepsis Risk Calculator for Neonates Born to Mothers with Chorioamnionitis — PMID:29275925 - Association of Funisitis with Short-Term Outcomes of Prematurity: meta-analysis — PMID:36830092 - The Association between Term Chorioamnionitis during Labor and Long-Term Infectious Morbidity of the Offspring — PMID:38337508 - Suspected Chorioamnionitis and Myometrial Contractility — PMID:29848185 - Impact of microbial invasion of amniotic cavity and type of microorganisms on neonatal outcome — PMID:28094842 - Chorioamnionitis caused by Listeria monocytogenes: ultrasound features — PMID:23429225 - Fetal heart rate patterns complicated by chorioamnionitis and subsequent cerebral palsy — PMID:36433630

PMC / journal full text: - Association of Histological and Clinical Chorioamnionitis With Neonatal Sepsis: meta-analysis (Front Immunol 2020) - Uncultivated Bacteria as Etiologic Agents of Intra-Amniotic Inflammation Leading to Preterm Birth (J Clin Microbiol 2008) - HMGB1 Induces an Inflammatory Response in the Chorioamniotic Membranes (Biol Reprod 2016) - IL-1 Receptor Blockade Prevents Fetal Cortical Brain Injury But Not Preterm Birth - Intra-amniotic LPS causes acute neuroinflammation in preterm rhesus macaques - Airway inflammatory cell responses to intra-amniotic LPS in a sheep model of chorioamnionitis - Inflammation in fetal sheep from intra-amniotic injection of Ureaplasma parvum - TLR4 antagonist inhibits LPS-induced preterm uterine contractility in rhesus monkeys - Ureaplasma diversum lipoproteins activate inflammatory genes through NF-κB via TLR4 - Acute Histologic Chorioamnionitis at Term: Nearly Always Noninfectious - Polymorphisms in immunoregulatory genes and risk of histologic chorioamnionitis - Chorioamnionitis and Neonatal Outcomes (review) - Chorioamnionitis and Patent Ductus Arteriosus: systematic review and meta-analysis - Azithromycin vs erythromycin in PPROM: lower chorioamnionitis and endometritis - A population-based study of the risk of repeat clinical chorioamnionitis, Washington State 1989–2008 - Transcriptomic analysis of equine chorioallantois in nocardioform placentitis (Vet Res 2021) - Fusobacterium nucleatum Induces Premature and Term Stillbirths in Pregnant Mice (Infect Immun 2004) - Characterization of an Adapted Murine Model of Intrauterine Inflammation–Induced Preterm Birth (Am J Pathol 2019) - Proteomic Profiling of the Amniotic Fluid to Detect Inflammation, Infection, and Neonatal Sepsis (PLOS Med 2007) - Advances in Medical Diagnosis of Intra-Amniotic Infection

Guidelines, ontologies and reference resources: - ACOG — Intrapartum Management of Intraamniotic Infection (Committee Opinion 712) - ACOG — Prevention of Group B Streptococcal Early-Onset Disease in Newborns (2020) - AAP — Management of Infants at Risk for Group B Streptococcal Disease (Pediatrics 2019) - CDC — Clinical Overview of Group B Strep Disease - StatPearls — Chorioamnionitis (NCBI Bookshelf NBK532251) - Merck Manual Professional — Intraamniotic Infection (Chorioamnionitis) - Mondo Disease Ontology — Monarch Initiative - ICD-10-CM O41.12 Chorioamnionitis - Kaiser Permanente — Rate of Chorioamnionitis More than Doubled since 1995 - Frontiers in Medicine 2023 — Clinical chorioamnionitis: where do we stand now? - Intrauterine inflammation, infection, or both (Triple I): A new concept for chorioamnionitis (Pediatr Neonatol 2017)